Spero Therapeutics entered into a global license agreement for the anti-CD40L antibody SP001 with Innovent Biologics. The deal potentially worth $1.1 billion aims to expand Spero's pipeline into autoimmune diseases.
Spero Therapeutics entered into a global license agreement for the anti-CD40L antibody SP001 with Innovent Biologics. The deal potentially worth $1.1 billion aims to expand Spero's pipeline into autoimmune diseases.